How M.D. was paid
$10.7M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Peter Salzmann, M.D.Former Chief Executive Officer | $724,500 | $470,925 | $4,941,237 | $4,539,890 | $55,575 | $10,732,127 |
| Eva Renee BarnettFormer Chief Financial Officer | $481,000 | $216,450 | $1,692,223 | $1,554,789 | $26,272 | $3,970,734 |
| Michael Geffner, M.D.Chief Medical Officer | $518,000 | $233,100 | $1,692,223 | $1,554,789 | $52,915 | $4,051,027 |
| Melanie GloriaChief Operating Officer | $180,375 | $79,465 | $2,804,978 | $2,500,844 | $8,173 | $5,573,835 |
| Christopher Van TuylChief Legal Officer and Corporate Secretary | $140,292 | $62,860 | $3,038,084 | $2,699,742 | $7,361 | $5,948,339 |
What changed and why
- $10.7M$10,732,127 CEO total compensation increased from $8,552,430 in fiscal 2024.
- $9.5M$9,481,127 of CEO compensation consisted of stock and option awards.
- $471K$470,925 CEO bonus reflected company and individual performance objectives for fiscal 2025.
- 29:1 was the fiscal 2025 CEO-to-median-employee pay ratio.
- 97%97% of votes cast supported executive compensation at the 2024 annual meeting.
- April 2025 brought a new CEO and CFO after Salzmann and Barnett departed their roles.
Other Immunovant proxy statements
- 2026 proxy statement
Eric Venker, M.D., Pharm.D. paid $20.2M, pay ratio 67:1.
Filed Jul 22, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.